Home

DANIEL G WELCH

CIK 1206199 · Chairman, CEO and President · last filed 2026-06-18

DANIEL G WELCH is a Chairman, CEO and President who has filed 118 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for GPCR, was dated Jun 18, 2026. Across all open-market trades the lifetime net is −$34.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $7.5M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$7.53M

Companies

8

Total Filings

118

Lifetime Open-Market Net

-$34.94M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
GPCR Director 123,508 $52.13 $6.44M $0 5 2026-06-18
RARE Director 40,441 $26.96 $1.09M $0 13 2026-05-18
PRTA Director — $9.22 — $0 4 2026-05-15
Nuvation Bio Inc. (NUVB.WS) Delisted Director 659,947 $0.01 $3.4K $0 6 2024-05-29
Seagen Inc. (SGEN) Delisted Director 0 $228.74 $0 -$34.84M 31 2023-12-15
INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted Director 8,060 $19.00 $153.1K -$102.1K 8 2020-06-01
AveXis, Inc. (AVXS) Delisted Director 0 — — $0 4 2018-05-15
HYPERION THERAPEUTICS INC (HPTX) Delisted Director 0 — — $0 3 2015-05-08

Recent Filings

118 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-18 GPCR Grant (A) — $0 EDGAR
2026-05-18 RARE Grant (A) +7,751 $0 EDGAR
2026-05-15 PRTA Grant (A) — $0 EDGAR
2025-06-25 GPCR Grant (A) — $0 EDGAR
2025-05-19 RARE Grant (A) +5,740 $0 EDGAR
2025-05-16 PRTA Grant (A) — $0 EDGAR
2024-06-27 GPCR Grant (A) — $0 EDGAR
2024-06-20 RARE Grant (A) +5,345 $0 EDGAR
2024-05-29 Nuvation Bio Inc. (NUVB.WS) Delisted Exer (M) +659,947 $1.11M EDGAR
2024-05-17 PRTA Grant (A) — $0 EDGAR
Showing 1–10 of 118
Page 1 of 12
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.